Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, ...

RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead ...

Lung cancer remains one of the leading causes of cancer-related deaths worldwide, but the good news is that it can often be prevented, especially when people take proactive steps to reduce their ...

Puma Biotechnology ... invasive disease-free survival was 95.3% in patients treated with Nerlynx compared with 90.8% in those receiving placebo. The most common side effects were diarrhoea ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases.

Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...